Opinion

Video

Emerging Agents in Treatment of Rheumatic Diseases

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

00:00 Welcome and introductions

01:40 Novel therapeutic agents targeting pathophysiology of rheumatic diseases

06:15 IL-17A, IL-17F inhibitor bimekizumab

07:42 Tyk2 inhibitor deucravacitnib in rheumatology

09:50 IL-17A inhibitor izokibep in psoriatic arthritis

11:10 Outcome measures in rheumatic diseases

16:20 Molecular signature response classifier (MSRC) test

19:40 Biosimilars in rheumatology

24:30 Precision medicine in clinical practice

29:30 Role of advanced practice practitioners in rheumatology

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.